81 filings
8-K
EQ
Equillium Inc
1 Apr 24
Other Events
8:05am
8-K
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
8-K
EQ
Equillium Inc
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
EQ
Equillium Inc
23 Feb 24
Results of Operations and Financial Condition
5:12pm
8-K
EQ
Equillium Inc
22 Feb 24
Other Events
6:08am
8-K
wl7pw5czvbvhn7jys10
21 Dec 23
Other Events
8:05am
8-K
1nc4fbq5h4pawd
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
538bw6f 8a
16 Oct 23
Regulation FD Disclosure
8:05am
8-K
k6kcg0dzhhgz9 b89r
5 Oct 23
Entry into a Material Definitive Agreement
5:28pm
8-K
lnd70ri irudxag
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
qsbx6 3n7uist
25 May 23
Termination of a Material Definitive Agreement
4:00pm
8-K
68bc qww8v
23 May 23
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
ijkib8rug 4rvvyxfca1
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
8-K
f27ws7yiho0uw8qrrte
6 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:02pm
8-K
e92x4nnv5ote6
23 Mar 23
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides CorporateĀ & Clinical Development Updates
4:05pm
8-K
zqpzeo
23 Dec 22
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
4:11pm
8-K
rs8pjqk5
14 Dec 22
Other Events
9:49pm
8-K
wpt5b4g
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
8-K
gqevns0
14 Nov 22
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
4:10pm
8-K
jz7s8
27 Sep 22
Other Events
9:28am